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Abstract
Background
Converging evidence suggests that immune-mediated dysfunction plays an important role
in the pathogenesis of frontotemporal dementia (FTD). Although genetic studies have
shown that immune-associated loci are associated with increased FTD risk, a systematic
investigation of genetic overlap between immune-mediated diseases and the spectrum of
FTD-related disorders has not been performed.
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Methods and findings
Using large genome-wide association studies (GWASs) (total n = 192,886 cases and con-
trols) and recently developed tools to quantify genetic overlap/pleiotropy, we systematically
identified single nucleotide polymorphisms (SNPs) jointly associated with FTD-related disor-
ders—namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy
(PSP), and amyotrophic lateral sclerosis (ALS)—and 1 or more immune-mediated diseases
including Crohn disease, ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes
(T1D), celiac disease (CeD), and psoriasis. We found up to 270-fold genetic enrichment
between FTD and RA, up to 160-fold genetic enrichment between FTD and UC, up to 180-
fold genetic enrichment between FTD and T1D, and up to 175-fold genetic enrichment
between FTD and CeD. In contrast, for CBD and PSP, only 1 of the 6 immune-mediated dis-
eases produced genetic enrichment comparable to that seen for FTD, with up to 150-fold
genetic enrichment between CBD and CeD and up to 180-fold enrichment between PSP
and RA. Further, we found minimal enrichment between ALS and the immune-mediated dis-
eases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold). For
FTD, at a conjunction false discovery rate < 0.05 and after excluding SNPs in linkage dis-
equilibrium, we found that 8 of the 15 identified loci mapped to the human leukocyte antigen
(HLA) region on Chromosome (Chr) 6. We also found novel candidate FTD susceptibility
loci within LRRK2 (leucine rich repeat kinase 2), TBKBP1 (TBK1 binding protein 1), and
PGBD5 (piggyBac transposable element derived 5). Functionally, we found that the expres-
sion of FTD–immune pleiotropic genes (particularly within the HLA region) is altered in post-
mortem brain tissue from patients with FTD and is enriched in microglia/macrophages
compared to other central nervous system cell types. The main study limitation is that the
results represent only clinically diagnosed individuals. Also, given the complex interconnec-
tedness of the HLA region, we were not able to define the specific gene or genes on Chr 6
responsible for our pleiotropic signal.
Conclusions
We show immune-mediated genetic enrichment specifically in FTD, particularly within the
HLA region. Our genetic results suggest that for a subset of patients, immune dysfunction
may contribute to FTD risk. These findings have potential implications for clinical trials tar-
geting immune dysfunction in patients with FTD.
Author summary
Why was this study done?
• Frontotemporal dementia (FTD) is the leading cause of dementia in individuals less
than 65 years old.
• Currently, there is no approved treatment of FTD and no diagnostic tests for predicting
disease onset or measuring progression.
• Increasing evidence suggests that inflammation and immune system dysfunction play
an important role in the pathogenesis of FTD.
Immune dysfunction in FTD
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002487 January 9, 2018 2 / 20
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE13162 are publicly available.
Funding: Primary support for data analyses was
provided by National Institutes of Health grants
AG046374 (CK), U24DA041123 (AD, LS, RD),
National Alzheimer’s Coordinating Center (NACC)
Junior Investigator (JI) Award (RD), RSNA
Resident/Fellow Grant (RD), Foundation of ASNR
Alzheimer’s Imaging Grant (RD), Alzheimer’s
Society Grant 284 (RF), ARRS/ASNR Scholar
Award (LS), and the Tau Consortium (JY, GDR).
Additional support was provided by the Larry L.
Hillblom Foundation 2016-A-005-SUP (JY), AFTD
Susan Marcus Memorial Fund Clinical Research
Grant (JY), NIA K01 AG049152 (JY), P01-AG-
017586 (GDS), and the Bluefield Project to Cure
FTD (JY). GH was funded by the Deutsche
Forschungsgemeinschaft (DFG, HO2402/6-2 &
Munich Cluster for Systems Neurology SyNergy),
the German Federal Ministry of Education and
Research (BMBF, 01KU1403A EpiPD, 01EK1605A
HitTau), the Bavarian Ministry for Education,
Culture, Science and Art (Grant 8810001412
ForIPS), the NOMIS foundation (FTLD project). The
PSP-GWAS was funded by a grant from the
CurePSP Foundation, the Peebler PSP Research
Foundation. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: OAA reports patent
pending for statistical genetics tool. OAA also
received speakers’s honorarium from Lundbeck.
JHV’s institute received consultancy fees from
Vertex Pharmaceuticals. JH reports consulting for
Cytox Genetics. AMD reports that he is a Founder
of and holds equity in CorTechs Labs, Inc., and
serves on its Scientific Advisory Board. AMD is a
member of the Scientific Advisory Board of Human
Longevity, Inc., and receives funding through
research grants with General Electric Healthcare
(the terms of these arrangements have been
reviewed by and approved by the University of
California, San Diego in accordance with its conflict
of interest policies). AMD has a pending patent
entitled “SYSTEMS AND METHODS FOR
IDENTIFYING POLYMORPHISMS” through UC San
Diego. GDR declared to receive research support
from Avid Radiopharmaceuticals, Eli Lilly, GE
Healthcare and Piramal. GDR also served on
Scientific Advisory Boards for: Merck, Genentech,
Roche. BM is a member of the Editorial Board of
PLOS Medicine.
Abbreviations: ALS, amyotrophic lateral sclerosis;
CBD, corticobasal degeneration; CD, Crohn
What did the researchers do and find?
• We used summary data from genome-wide association studies to investigate genetic
overlap, or “pleiotropy,” between FTD and a variety of immune-mediated diseases.
• Through this approach, we found extensive FTD–immune genetic overlap within the
HLA region on Chromosome 6, an area rich in genes related to microglial function, as
well as in 3 genes not previously identified as contributing to the pathophysiology of
FTD.
• Pointing to the functional relevance of these genetic results, we found that these candi-
date FTD–immune genes are differentially expressed in postmortem brains from
patients with FTD compared to controls, and in microglia/macrophages compared with
other central nervous system cells.
• Using bioinformatics tools, we explored protein and genetic interactions among our
candidate FTD–immune genes. These results suggest that rather than a few individual
loci, large portions of the HLA region may be associated with increased FTD risk.
What do these findings mean?
• Immune dysfunction may play a role in the pathophysiology of a subset of FTD cases.
• For a subset of patients in whom immune dysfunction in general—and microglial acti-
vation in particular—is central to disease pathophysiology, anti-inflammatory treatment
is an important area for further investigation.
Introduction
Frontotemporal dementia (FTD) is a fatal neurodegenerative disorder and the leading cause of
dementia among individuals younger than 65 years of age [1]. Given rapid disease progression
and the absence of disease-modifying therapies, there is an urgent need to better understand
FTD pathobiology to accelerate development of novel preventive and therapeutic strategies.
Converging molecular, cellular, genetic, and clinical evidence suggests that neuroinflamma-
tion plays a role in FTD pathogenesis. Complement factors and activated microglia, key com-
ponents of inflammation, have been established as histopathologic features in brains of
patients [2] and in mouse models of FTD [3,4]. Genome-wide association studies (GWASs)
have shown that single nucleotide polymorphisms (SNPs) within the immune-regulating
human leukocyte antigen (HLA) region on Chromosome (Chr) 6 are associated with elevated
FTD risk [5]. Importantly, there is increased prevalence of immune-mediated diseases among
patients with FTD [6,7]. Together, these findings suggest that immune-related mechanisms
may contribute to and potentially drive FTD pathology.
Recent work in human molecular genetics has emphasized “pleiotropy,” where variations
in a single gene can affect multiple, seemingly unrelated phenotypes [8]. In the present study,
we systematically evaluated genetic pleiotropy between FTD and immune-mediated diseases.
Using large neurodegenerative GWASs and recently developed tools to estimate polygenic
pleiotropy, we sought to identify SNPs jointly associated with FTD-related disorders [9,10]—
namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and
Immune dysfunction in FTD
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amyotrophic lateral sclerosis (ALS)—and 1 or more immune-mediated diseases including
Crohn disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D),
celiac disease (CeD), and psoriasis (PSOR).
Methods
Participant samples
We conducted a meta-analysis of summary data obtained from published data. More specifi-
cally, we evaluated complete GWAS results in the form of summary statistics (p-values and
odds ratios) for FTD, CBD, PSP, and ALS and 6 immune-mediated diseases, including CD
[11], UC [12], RA [13], T1D [14], CeD [15], and PSOR [16] (see Table 1). We obtained FTD
GWAS summary statistic data from phase I of the International FTD-Genomics Consortium
(IFGC), which consisted of 2,154 clinical FTD cases and 4,308 controls with genotyped and
imputed data at 6,026,384 SNPs (Table 1; for additional details, see [5]). The FTD dataset
included multiple clinically diagnosed FTD subtypes: behavioral variant (bvFTD), semantic
dementia (sdFTD), primary nonfluent progressive aphasia (pnfaFTD), and FTD overlapping
with motor neuron disease (mndFTD). These FTD cases and controls were recruited from
44 international research groups and diagnosed according to the Neary criteria [17]. The insti-
tutional review boards of all participating institutions approved the procedures for all IFGC
sub-studies. Written informed consent was obtained from all participants or surrogates. We
obtained CBD GWAS summary statistic data from 152 CBD cases and 3,311 controls at
533,898 SNPs (Table 1; for additional details, see [18]). The CBD cases were collected from 8
institutions, and controls were recruited from the Children’s Hospital of Philadelphia. CBD
was neuropathologically diagnosed using the National Institutes of Health Office of Rare Dis-
eases Research criteria [19]. The institutional review boards of all participating institutions
approved the procedures for CBD GWAS data. Written informed consent was obtained
from all participants or surrogates. We obtained PSP GWAS summary statistic data (stage 1)
from the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIA-
GADS, https://www.niagads.org) for 1,114 individuals with autopsy-confirmed PSP and 3,247
controls at 531,451 SNPs (Table 1; for additional details, see [20]). The institutional review
boards of all participating institutions approved the procedures for all NIAGADS sub-studies.
Written informed consent was obtained from all participants or surrogates. We obtained ALS
GWAS summary statistic data from 12,577 ALS cases and 23,475 controls at 18,741,501 SNPs
(Table 1; for additional details, see [21]). The ALS GWAS summary statistics and sequenced
variants are publicly available through the Project MinE Data Browser (http://databrowser.
projectmine.com). The institutional review boards of all participating institutions approved
Table 1. Summary data from all genome-wide association studies used in the current study.
Disorder/disease Abbreviation Total N Number of SNPs Reference
Frontotemporal dementia FTD 6,462 6,026,384 [5]
Corticobasal degeneration CBD 3,463 533,898 [18]
Progressive supranuclear palsy PSP 4,361 531,451 [20]
Amyotrophic lateral sclerosis ALS 36,052 18,741,501 [21]
Crohn disease CD 51,109 942,858 [11]
Ulcerative colitis UC 26,405 1,273,589 [12]
Rheumatoid arthritis RA 25,708 2,554,714 [13]
Type 1 diabetes T1D 16,559 841,622 [14]
Celiac disease CeD 15,283 528,969 [15]
Psoriasis PSOR 7,484 1,121,166 [16]
https://doi.org/10.1371/journal.pmed.1002487.t001
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the procedures for all ALS GWAS sub-studies. Written informed consent was obtained from
all participants or surrogates.
Genetic enrichment statistical analyses
The pleiotropic enrichment strategies implemented here were derived from previously pub-
lished stratified false discovery rate (FDR) methods [22,23]. For given phenotypes A and B,
pleiotropic “enrichment” between phenotype A and phenotype B exists if the proportion of
SNPs or genes associated with phenotype A increases as a function of increased association
with phenotype B. To assess for enrichment, we constructed fold enrichment plots of nominal
−log10(p)-values for all FTD-related-disorder SNPs and for subsets of SNPs determined by the
significance of their association with the 6 immune-mediated diseases. In fold enrichment
plots, the presence of enrichment is reflected as an upward deflection of the curve for pheno-
type A with increasing strength of association with phenotype B. To assess for polygenic effects
below the standard GWAS significance threshold, we focused the fold enrichment plots on
SNPs with nominal −log10(p)< 7.3 (corresponding to p> 5 × 10−8). The enrichment seen can
be directly interpreted in terms of the true discovery rate (1 − FDR).
To identify specific loci jointly involved with each of the 4 FTD-related disorders and the 6
immune-mediated diseases, we computed conjunction FDRs. The conjunction FDR is a test of
association between 2 traits [22]. Briefly, the conjunction FDR, denoted by FDRtrait1& trait2, is
defined as the posterior probability that a SNP is null for either trait or for both simultaneously,
given that the p-values for both traits are as small, or smaller, than the observed p-values. Unlike
the conditional FDR, which ranks disease/primary-phenotype-associated SNPs based on genetic
“relatedness” with secondary phenotypes [24], the conjunction FDR minimizes the possibility/like-
lihood of a single phenotype driving the common association signal. The conjunction FDR there-
fore tends to be more conservative and specifically pinpoints pleiotropic loci shared between the
traits/diseases of interest. We used an overall FDR threshold of<0.05, which means 5 expected
false discoveries per 100 reported. To visualize the results of our conjunction FDR analysis, we
constructed Manhattan plots to illustrate the genomic location of the pleiotropic loci. We ranked
all SNPs based on the conjunction FDR and removed SNPs in linkage disequilibrium (r2> 0.2)
with any higher ranked SNP. Key aspects and detailed information on fold enrichment plots,
Manhattan plots, and conjunction FDRs can be found in prior reports [22,23,25,26].
Functional evaluation of shared risk loci
To assess whether SNPs that are shared between FTD and immune-mediated disease modify
gene expression, we identified cis-expression quantitative trait loci (cis-eQTLs, defined as vari-
ants within 1 Mb of a gene’s transcription start site) associated with shared FTD–immune
SNPs and measured their regional brain expression in a publicly available dataset of normal
control brains (UK Brain Expression Consortium; http://braineac.org/) [27]. We also evalu-
ated cis-eQTLs using a blood-based dataset [28]. We applied an analysis of covariance
(ANCOVA) to test for associations between genotypes and gene expression. We tested SNPs
using an additive model.
Network-based functional association analyses
To evaluate potential protein and genetic interactions, co-expression, co-localization, and
protein domain similarity for the functionally expressed (i.e., with significant cis-eQTLs)
pleiotropic genes, we used GeneMANIA (http://genemania.org), an online web portal for bio-
informatic assessment of gene networks [29]. In addition to visualizing the composite gene
network, we also assessed the weights of individual components within the network [30].
Immune dysfunction in FTD
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Gene expression alterations in FTD brains
To determine whether functionally expressed (i.e., with significant cis-eQTLs) pleiotropic
genes are differentially expressed in the brains of FTD patients, we analyzed the gene expres-
sion of pleiotropic genes. Postmortem expression data from the brains of 17 patients with fron-
totemporal lobar degeneration with ubiquitinated inclusions (FTD-U) (with and without
progranulin [GRN] mutations) and 11 controls were obtained from a publically available data-
set (Gene Expression Omnibus [GEO] dataset GSE13162; for additional details, see [31]).
These data consist of global gene expression profiles from all histopathologically available
regions from human FTD-U and control brains (frontal cortex, hippocampus, and cerebel-
lum) analyzed on the Affymetrix U133A microarray platform. Given the small sample size of
each individual region, we combined all 3 regions to maximize statistical power. Details about
this dataset and analysis—including the human brain samples used, RNA extraction and
hybridization methods, microarray quality control, and microarray data analysis—are pro-
vided in the original report [31].
Evaluation of cell classes within the brain
Using a publicly available RNA-sequencing transcriptome and splicing database [32], we
ascertained whether the functionally expressed (i.e., with significant cis-eQTLs) pleiotropic
genes were expressed by specific cell classes within the brain. The 8 cell types surveyed were
neurons, fetal and mature astrocytes, oligodendrocyte precursor cells, newly formed oligoden-
drocytes, myelinating oligodendrocytes, microglia/macrophages (henceforth “microglia”),
endothelial cells, and pericytes (for additional details, see [32]).
Results
Shared genetic risk between FTD and immune-mediated disease
Using progressively stringent p-value thresholds for FTD SNPs (i.e., increasing values of nomi-
nal −log10[p]), we observed genetic enrichment for FTD as a function of several immune-
mediated diseases (Fig 1). More specifically, we found strong (up to 270-fold) genetic enrich-
ment between FTD and RA, and comparable enrichment between FTD and UC, T1D, and
CeD, with weaker enrichment between FTD and PSOR and CD.
At a conjunction FDR < 0.05, we identified 21 SNPs that were associated with both FTD
and immune-mediated diseases (Fig 2; Table 2). Five of these SNPs demonstrated the opposite
direction of allelic effect between FTD and the immune-mediated diseases (Table 2): (1)
rs9261536, nearest gene = TRIM15; (2) rs3094138, nearest gene = TRIM26; (3) rs9268877,
nearest gene = HLA-DRA; (4) rs10484561, nearest gene = HLA-DQB1; and (5) rs2269423,
nearest gene = AGPAT1. Of the remaining 16, 2 SNPs showed strong linkage disequilibrium
(LD), suggesting that they reflected the same signal: rs204991 and rs204989 (nearest gene:
GPSM3; pairwise D0 = 1, r2 = 1). After excluding SNPs that demonstrated the opposite direc-
tion of allelic effect and SNPs that were in LD, we found that 8 of the remaining 15 identified
loci mapped to the HLA region, suggesting that HLA markers were critical in driving our
results. To test this hypothesis, we repeated our enrichment analysis after removing all SNPs in
LD with r2 > 0.2 within 1 Mb of HLA variants (based on 1000 Genomes Project LD structure).
After removing HLA SNPs, we saw considerable attenuation of genetic enrichment in FTD as
a function of immune-mediated disease (Fig 3), suggesting that the observed overlap between
immune-related diseases and FTD was largely driven by the HLA region. Further, to determine
causal associations for FTD and the 6 immune-mediated diseases, we applied the recently
developed summary-data-based Mendelian randomization (SMR; http://cnsgenomics.com/
Immune dysfunction in FTD
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software/smr/) method. This approach is described in detail within the original report [33]. As
shown in S1 Table, results from the SMR analysis have identified significant loci that are con-
sistent with the main findings, which suggest that HLA markers on Chr 6 are critical in driving
our pleiotropic results.
Outside the HLA region, we found 7 other FTD- and immune-associated SNPs (Fig 2;
Table 2), including 2 in strong LD that mapped to the H1 haplotype of microtubule associated
protein tau (MAPT) (LD: rs199533 and rs17572851; nearest genes: NSF and MAPT, pairwise
D0 = 1, r2 = 0.94). Beyond MAPT, we found 5 additional novel loci associated with increased
FTD risk, namely, (1) rs2192493 (Chr 7, nearest gene = TWISTNB), (2) rs7778450 (Chr 7,
nearest gene = TNS3), (3) rs10216900 (Chr 8, nearest gene = CR590356), (4) rs10784359 (Chr
12, nearest gene = SLC2A13), and (5) rs2134297 (Chr 18, nearest gene = DCC) (see Table 2 for
additional details).
Modest genetic enrichment between immune-mediated disease and
PSP, CBD, and ALS
To evaluate the specificity of the shared genetic overlap between FTD and immune-mediated
disease, we also evaluated overlap between the 6 immune-mediated diseases and CBD, PSP,
and ALS. For CBD and PSP, a few of the immune-mediated diseases produced genetic
Fig 1. Fold enrichment plots of enrichment versus nominal −log10(p)-values (corrected for inflation) in frontotemporal dementia
(FTD) below the standard genome-wide association study threshold of p < 5 × 10−8 as a function of significance of association
with 6 immune-mediated diseases. The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes
(T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log10(p) > 0, −log10(p) > 1, and −log10(p) > 2
correspond to p < 1, p < 0.1, and p < 0.01, respectively. The dark blue line indicates all SNPs.
https://doi.org/10.1371/journal.pmed.1002487.g001
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enrichment comparable to that seen for FTD (S1–S3 Figs; S2–S4 Tables). For example, we
found 150-fold genetic enrichment between CBD and CeD and 180-fold enrichment between
PSP and RA. In contrast, we found minimal enrichment between ALS and the immune-medi-
ated diseases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold)
and between ALS and CeD (up to 15-fold).
At a conjunction FDR < 0.05, we identified several SNPs associated with both immune-
mediated disease and CBD, PSP, or ALS (S4–S6 Figs; S2–S4 Tables). Few of the SNPs shared
between CBD, PSP, or ALS and immune-mediated disease mapped to the HLA region. Only 2
PSP–immune SNPs mapped to the region of MLN and IRF4 on Chr 6, and no CBD–immune
or ALS–immune SNPs mapped to the HLA region (S4–S6 Figs; S2–S4 Tables).
Beyond the HLA region, we found several overlapping loci between the immune- mediated
diseases and CBD, PSP, and ALS (S4–S6 Figs; S2–S4 Tables). For PSP, these were (1) rs7642229
with CeD (Chr 3, nearest gene = XCR1, FDR = 1.74 × 10−2); (2) rs11718668 with CeD (Chr 3,
nearest gene = TERC, FDR = 3.00 × 10−2); (3) rs12203592 with CeD (Chr 6, nearest gene =
IRF4, FDR = 4.17× 10−2); (4) rs1122554 with RA (Chr 6, nearest gene =MLN, FDR = 2.09× 10−2);
and (5) rs3748256 with RA (Chr 11, nearest gene = FAM76B, FDR = 2.09 × 10−2). For ALS,
these were (1) rs3828599 with CeD (Chr 5, nearest gene = GPX3, FDR = 2.27 × 10−2) and (2)
rs10488631 with RA (Chr 7, nearest gene = TNPO3, FDR = 3.42 × 10−2).
Fig 2. “Conjunction” Manhattan plot of conjunction −log10(FDR) values for frontotemporal dementia (FTD) given 6 immune-mediated
diseases. The 6 immune-related diseases were Crohn disease (CD; FTD|CD, red), ulcerative colitis (UC, FTD|UC, orange), type 1 diabetes (T1D,
FTD|T1D, teal), rheumatoid arthritis (RA, FTD|RA, green), celiac disease (CeD, FTD|CeD, magenta), and psoriasis (PSOR, FTD|PSOR, blue).
SNPs with conjunction −log10(FDR) > 1.3 (i.e., FDR < 0.05) are shown with large points. A black line around the large points indicates the most
significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each
locus.
https://doi.org/10.1371/journal.pmed.1002487.g002
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cis-eQTL expression
To investigate whether shared FTD–immune SNPs modify gene expression, we evaluated cis-
eQTLs in both brain and blood tissue types. At a previously established conservative Bonfer-
roni-corrected p-value< 3.9 × 10−5 [34], we found significant cis-associations between shared
SNPs and genes in the HLA region on Chr 6 in peripheral blood mononuclear cells, lympho-
blasts, and the human brain (see S5 Table for gene expression associated with each SNP). We
also found that rs199533 and rs17572851 on Chr 17 were significantly associated with MAPT
(p = 2 × 10−12) expression in the brain. Beyond the HLA and MAPT regions, notable cis-eQTLs
included rs10784359 and LRRK2 (p = 1.40 × 10− 7) and rs2192493 and TBKBP1
(p = 1.29 × 10−6) (see S5 Table).
Protein–protein and co-expression networks
We found physical interaction and gene co-expression networks for the FTD–immune pleio-
tropic genes with significant cis-eQTLs (at a Bonferroni-corrected p-value< 3.9 × 10−5). We
found robust co-expression between various HLA classes, further suggesting that large por-
tions of the HLA region, rather than a few individual loci, may be involved with FTD (Fig 4; S6
Table). Interestingly, we found that several non-HLA functionally expressed FTD–immune
genes, namely, LRRK2, PGBD5, and TBKBP1, showed co-expression with HLA-associated
genes (Fig 4).
Table 2. Overlapping loci between FTD and immune-mediated disease at a conjunction FDR < 0.05.
SNP Chr Nearest
gene
Reference immune
disease
Reference immune disease
p-value
Minimum conjunction
FDR
FTD p-value Direction of allelic
effect
rs2269423 6 AGPAT1 CeD 4.63 × 10−2 4.63 × 10−2 6.28 × 10−1 +/−
rs3117097 6 BTNL2 RA 8.21 × 10−5 8.21 × 10−5 7.19 × 10−3 +/+
rs204989 6 GPSM3 UC 2.90 × 10−2 9.02 × 10−3 2.58 × 10−1 +/+
rs204991 6 GPSM3 T1D 1.00 × 10−2 9.02 × 10−3 2.58 × 10−1 +/+
rs17427887 6 HLA-DQA2 RA 3.70 × 10−2 3.70 × 10−2 6.02 × 10−1 −/−
rs10484561 6 HLA-DQB1 T1D 1.86 × 10−2 1.71 × 10−2 4.17 × 10−1 −/+
rs3135353 6 HLA-DRA CD 2.29 × 10−2 3.58 × 10−3 1.35 × 10−1 +/+
rs9268852 6 HLA-DRA UC 1.25 × 10−7 1.25 × 10−7 1.03 × 10−4 +/+
rs3129890 6 HLA-DRA T1D 5.54 × 10−5 5.54 × 10−5 7.19 × 10−3 +/+
rs6457590 6 HLA-DRA RA 1.52 × 10−2 1.52 × 10−2 3.80 × 10−1 +/+
rs9268877 6 HLA-DRA RA 3.64 × 10−7 1.25 × 10−7 1.03 × 10−4 +/−
rs875142 6 PAQR8 CD 4.62 × 10−2 4.62 × 10−2 5.51 × 10−1 −/−
rs9261536 6 TRIM15 T1D 4.31 × 10−2 4.31 × 10−2 6.98 × 10−1 −/+
rs3094138 6 TRIM26 T1D 4.63 × 10−2 2.87 × 10−2 6.28 × 10−1 −/+
rs7778450 7 TNS3 CeD 4.26 × 10−2 4.26 × 10−2 6.17 × 10−1 −/−
rs2192493 7 TWISTNB T1D 4.17 × 10−2 4.17 × 10−2 6.09 × 10−1 +/+
rs10216900 8 CR590356 T1D 3.09 × 10−2 3.09 × 10−2 6.40 × 10−1 +/+
rs10784359 12 SLC2A13 RA 3.33 × 10−2 3.33 × 10−2 5.90 × 10−1 +/+
rs17572851 17 MAPT T1D 2.47 × 10−2 2.47 × 10−2 5.90 × 10−1 +/+
rs199533 17 NSF CD 3.90 × 10−2 1.95 × 10−2 4.56 × 10−1 +/+
rs2134297 18 DCC CeD 3.11 × 10−2 3.11 × 10−2 5.73 × 10−1 +/+
CD, Crohn disease; CeD, celiac disease; Chr, Chromosome; FDR, false discovery rate; FTD, frontotemporal dementia; RA, rheumatoid arthritis; SNP,
single nucleotide polymorphism; T1D, type 1 diabetes; UC, ulcerative colitis; −, negative effect estimate; +, positive effect estimate.
https://doi.org/10.1371/journal.pmed.1002487.t002
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Genetic expression in FTD brains compared to controls
To investigate whether the FTD–immune pleiotropic genes with significant cis-eQTLs are dif-
ferentially expressed in FTD brains, we compared gene expression in FTD-U brains to that in
brains from neurologically healthy controls. We found significantly different levels of HLA
gene expression in FTD-U brains compared to control brains (Table 3). This was true of
FTD-U brains regardless of progranulin gene (GRN) mutation status. In spite of the fact that
the FTD GWAS used to identify these genes was based on patients with sporadic FTD (without
GRN mutations), GRN mutation carriers showed the greatest differences in HLA gene expres-
sion (Fig 5; Table 3). These findings are compatible with prior work showing microglial-medi-
ated immune dysfunction in GRN mutation carriers [3].
Microglial enrichment
For the FTD–immune pleiotropic genes with significant cis-eQTLs, across different central
nervous system (CNS) cell types, we found significantly greater expression within microglia
compared to neurons or fetal astrocytes (Fig 6A; Table 4). Interestingly, HLA genes showed
the greatest degree of differential expression. Four of the FTD–immune HLA-associated genes,
namely HLA-DRA, AOAH, HLA-A, and HLA-C, showed highest expression in microglia
(ranging from 10 to 60 fragments per kilobase of transcript per million; see Fig 6B). In
Fig 3. Fold enrichment plots of enrichment (after removing all regions in linkage disequilibrium with HLA on
Chromosome 6) versus nominal −log10(p)-values (corrected for inflation) in frontotemporal dementia (FTD) below the
standard genome-wide association study threshold of p < 5 × 10−8 as a function of significance of association with 6
immune-mediated diseases. The 6 immune-mediated diseases were Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes
(T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log10(p) > 0, −log10(p) > 1, and
−log10(p) > 2 correspond to p < 1, p < 0.1, and p < 0.01, respectively. The dark blue line indicates all SNPs.
https://doi.org/10.1371/journal.pmed.1002487.g003
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addition, MAPT was predominantly expressed in neurons, LRRK2 in microglia, PGBD5 in
neurons, and TBKBP1 in fetal astrocytes (Figs 6B and S7–S9).
Discussion
We systematically assessed genetic overlap between 4 FTD-related disorders and several
immune-mediated diseases. We found extensive genetic overlap between FTD and immune-
mediated disease particularly within the HLA region on Chr 6, a region rich in genes associ-
ated with microglial function. This genetic enrichment was specific to FTD and did not extend
Fig 4. Network interaction graph predominantly illustrating co-expression and shared protein domains for functionally
expressed pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases.
https://doi.org/10.1371/journal.pmed.1002487.g004
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to CBD, PSP, or ALS. Further, we found that shared FTD–immune gene variants were differ-
entially expressed in FTD patients compared with controls, and in microglia compared with
other CNS cells. Beyond the HLA region, by leveraging statistical power from large immune-
mediated GWASs, we detected novel candidate FTD associations requiring validation within
LRRK2, TBKBP1, and PGBD5. Considered together, these findings suggest that various micro-
glia and inflammation-associated genes, particularly within the HLA region, may play a critical
and selective role in FTD pathogenesis.
By combining GWASs from multiple studies and applying a pleiotropic approach, we iden-
tified genetic variants jointly associated with FTD-related disorders and immune-mediated
disease. We found that the strength of genetic overlap with immune-mediated disease varies
markedly across FTD-related disorders, with the strongest pleiotropic effects associated with
FTD, followed by CBD and PSP, and the weakest pleiotropic effects associated with ALS. We
identified 8 FTD- and immune-associated loci that mapped to the HLA region, a concentra-
tion of loci that was not observed for the other disorders. Indeed, only 2 PSP–immune pleio-
tropic SNPs and no CBD–immune or ALS–immune pleiotropic SNPs mapped to the HLA
region. Previous work has identified particular HLA genes associated with CBD, PSP, and ALS
[35,36]. In contrast, our current findings implicate large portions of the HLA region in the
pathogenesis of FTD. Together, these results suggest that each disorder across the larger FTD
spectrum has a unique relationship with the HLA region.
Our results also indicate that functionally expressed FTD–immune shared genetic variants
are differentially expressed in FTD brains compared to controls and in microglia compared to
other CNS cell types (Fig 6). Microglia play a role in the pathophysiology of GRN+ FTD. Pro-
granulin is expressed in microglia [37], and GRN haploinsufficiency is associated with abnor-
mal microglial activation and neurodegeneration [3]. It is perhaps expected, therefore, that
GRN+ brains show differential expression of FTD–immune genes, even though these genetic
variants were derived from a GWAS of patients with sporadic FTD (who lack GRN or other
established FTD mutations). More surprising is the presence of similar enrichment in GRN
− brains, suggesting that dysfunction of microglial-centered immune networks may be a com-
mon feature of FTD pathogenesis.
By leveraging statistical power from the large immune-mediated GWASs, we identified
novel candidate FTD associations requiring validation within LRRK2, TBKBP1, and PGBD5
Table 3. Genes associated with frontotemporal dementia (FTD) and immune-mediated disease differ-
entially altered in patients with frontotemporal lobar degeneration with ubiquitinated inclusions
(FTD-U) versus controls.
Gene Control versus FTD-U p-value Control versus GRN+ p-value
AOAH 0.631 0.013
HLA-A 0.622 0.004
HLA-C 0.372 0.002
HLA-F 0.592 0.001
HLA-DRA (LOC101060835) 0.017 0.008
HLA-DRQ (HLA-DQB1) 0.009 0.001
MAPT 0.376 0.090
TBKBP1 0.005 0.108
PGBD5 0.528 0.016
LRRK2 N/A N/A
p-Values 0.05 are in bold.
N/A, not available.
https://doi.org/10.1371/journal.pmed.1002487.t003
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and confirmed previously shown FTD-associated signal within the MAPT region. LRRK2
mutations are a cause of Parkinson disease [38] and CD [39]. We previously described a poten-
tial link between FTD and the LRRK2 locus [40], and another study using a small sample
showed that LRRK2 mutations may increase FTD risk [41]. Together, these results suggest that
the extended LRRK2 locus might influence FTD despite common genetic variants within
LRRK2 not reaching genome-wide significance in a large FTD GWAS [5]. We suggest that
increased expression of LRRK2 in microglia results in proinflammatory responses, possibly by
modulating TNF-alpha secretion [42]. TBKBP1 also modulates TNF-alpha signaling by bind-
ing to TBK1 (TANK binding kinase 1) [43]; rare pathogenic variants in TBK1 cause FTD-ALS
[44–46]. Importantly, elevated CSF levels of TNF-alpha are a core feature of FTD [6,47]. Build-
ing on these findings, in our bioinformatics “network”-based analysis, we found that both
LRRK2 and TBKBP1 interact with genes within the HLA region (Fig 4). Further, physical inter-
actions between MAPT and the HLA network are compatible with research suggesting that
under different conditions reactive microglia can either drive or mitigate tau pathology
[48,49]. MAPT mutations, which disrupt the normal binding of tau protein to tubulin, account
for a large proportion of familial FTD cases [50]. Together, these findings suggest that LRRK2,
TBKBP1, and MAPT may, at least in part, influence FTD pathogenesis via HLA-related
mechanisms.
Fig 5. Pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases are elevated in brains of patients
with FTD with GRN mutation. Expression for the genes with the largest effect sizes are plotted: (A) HLA-A, (B) HLA-C, (C) HLA-DRQ, and
(D) HLA-DRA. Expression values were obtained from GSE13162 for FTD-U brains with and without GRN mutations and neuropathology-free
controls. Horizontal bar represents mean ± SEM.
https://doi.org/10.1371/journal.pmed.1002487.g005
Immune dysfunction in FTD
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002487 January 9, 2018 13 / 20
Fig 6. Microglia enrichment in genes associated with frontotemporal dementia (FTD) and immune-mediated disease. FTD–immune genes
were analyzed to determine the cell type in which each gene was most highly expressed [32]. (A) Bar plots showing the relative number of genes most
highly expressed in each cell type. No genes were most highly expressed in endothelial cells or oligodendrocytes. See Table 4 for individual gene
names. (B) Individual bar plots showing cell-type-specific expression for genes with the largest effect size. Note that the horizontal scale is not the
same in all the plots. FPKM, fragments per kilobase of transcript per million.
https://doi.org/10.1371/journal.pmed.1002487.g006
Table 4. Enrichment of genes associated with frontotemporal dementia (FTD) and immune-mediated
disease in microglia compared with other central nervous system cells.
Gene Most enriched cell type
AOAH Microglia/macrophage
HLA-A Microglia/macrophage
HLA-C Microglia/macrophage
HLA-F Neurons
HLA-DRA Microglia/macrophage
HLA-DRQ Not found
LRRC37A3 Microglia/macrophage
MAPT Neurons
TRAM2 Fetal astrocytes
No genes were most highly expressed in endothelial cells or oligodendrocytes.
https://doi.org/10.1371/journal.pmed.1002487.t004
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This study has limitations. Particularly, in the original datasets that form the basis of our
analysis, diagnosis of FTD was established clinically. Given the clinical overlap among neuro-
degenerative diseases, we cannot exclude the potential influence of clinical misdiagnosis. As
such, our findings would benefit from confirmation in large pathologically confirmed cohorts.
In addition, given the complex interconnectedness of the HLA region (see Fig 4), we also were
not able to define the specific gene or genes on Chr 6 responsible for our pleiotropic signal.
However, given the number of HLA loci associated with increased FTD risk, it may be the case
that no single HLA variant will be clinically informative; rather, an additive combination of
these microglia-associated genetic variants may better inform FTD risk. This possibility is sup-
ported by our observation that the expression levels of FTD-immune shared genetic variants
differ on average between FTD brains and controls, but with considerable overlap between the
two groups, again suggesting that no single variant is likely to be the determinant of FTD risk
(Fig 5). Further, we acknowledge the lack of transcriptomic and epigenetic data that would
help to identify possible causal associations and mechanisms driving our pleotropic signal.
In conclusion, across a large cohort (total n = 192,886 cases and controls), we used pleiot-
ropy between FTD-related disorders and immune-mediated disease to identify several genes
within the HLA region that are expressed within microglia and differentially expressed in the
brains of patients with FTD. Building on prior work [6,7], our results support a disease model
in which immune dysfunction is central to the pathophysiology of a subset of FTD cases.
These findings have important implications for future work in FTD focused on monitoring
microglial activation as a marker of disease progression and investigating anti-inflammatory
treatments as modifiers of disease outcome.
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